Cosmos Health Inc. announced the initiation of the development of Cloudscreen 2.0, the new iteration of its Artificial Intelligence (AI) drug repurposing platform. With the integration of cutting-edge AI and machine learning technologies, Cloudscreen 2.0 builds on successful drug-protein interaction prediction algorithms, using advanced deep learning models and graph embedding techniques. It aims to predict interactions across the human proteome's complete structural landscape.

Furthermore, mutagenesis data for specific populations or diseases will be integrated, along with prediction tools for disordered proteins, which have emerged as significant players in several disease phenotypes. Significant improvements in prediction methods are expected to result from utilizing datasets of chemical and biological data that are over 100 times larger than those used in the original platform, with the goal of creating more robust predictions and achieving higher confidence scores. The updated planned infrastructure, in addition to Graphics Processing Unit (GPU) cloud services, will enable the scaling up to such amounts of data with updated prediction capabilities, setting a new standard for AI approaches in drug repurposing.

The integration of AI not only accelerates the identification of new therapeutic uses for existing drugs, but also enhances current comprehension of the molecular underpinnings of drug action and disease mechanisms.